Dr David Tan Boon Harn
|MBBS (SIN), FRCR (CLLINICAL ONCOLOGY, UK), FAMS (RADIATION ONCOLOGY)
|English, Mandarin Chinese, Cantonese Dialect, Hokkien Dialect
Dr David Tan Boon Harn is Medical Director and Senior Radiation Oncologist at Asian Alliance Radiation & Oncology (AARO), a private Singapore Radiation and Oncology group focusing on the use of advanced technologies to treat cancer.
He has more than 15 years of clinical experience and specializes in the treatment of Gynaecological Cancers (Cervix, Uterus & Ovarian), Lung cancers, Gastrointestinal cancers (Oesophagus, Stomach & Colorectal), and Hepatobiliary cancers (Liver, Pancreas & Gallbladder).
His clinical expertise is in the use of stereotactic radiosurgery and stereotactic body radiation therapy (SRS/SBRT), a highly targeted and ablative radiation treatment to treat primary and metastatic tumours in only 1-5 sessions. He is also fellowship- trained in Brachytherapy for gynaecological cancers.
Dr Tan is dual-trained in Chemotherapy and Radiotherapy, and well-versed with all modern radiation technologies including 3D conformal external beam radiotherapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Volumetric Arc Therapy (VMAT), Stereotactic Radiosurgery (SRS), Stereotactic Body Radiotherapy (SBRT), Deep Inspiration Breath Hold Radiotherapy, Gynaecology (cervix and endometrium) image-guided brachytherapy.
Dr. Tan graduated from the National University of Singapore in 2005 and commenced training in Radiation Oncology at the National Cancer Centre Singapore (NCCS) in 2007.
In 2011, Dr. Tan received the Health and Manpower Development (HMDP) Award for Advanced Training in Clinical Oncology in the UK. There, at the Mount Vernon Cancer Cancer in Middlesex, he obtained advanced training in general oncology and further subspecialized in the above tumour sites. He also trained under renowned experts in stereotactic radiosurgery and brachytherapy.
He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists in the UK (FRCR) in 2013 and was admitted as a Fellow of the Academy of Medicine, Singapore (FAMS) in Radiation Oncology in 2014.
Prior to joining AARO, Dr. Tan was a Consultant Radiation Oncologist at the National Cancer Centre Singapore (NCCS). During his 10 years of service in the public sector, he was responsible for setting up the Liver and Pancreas SBRT programs, and oversaw their development from protocol development to patient enrolment and subsequently to treatment of increasingly complex cases such as multiple liver metastases and portal vein thrombosis in hepatocellular carcinoma (HCC). He is also currently co-investigator in an international IAEA-led trial comparing SBRT with transarterial chemoembolization (TACE) in unresectable HCC.
Dr. Tan is the Singapore National Project Coordinator for the International Atomic Energy Agency (IAEA) Regional Project 6085, which aims to Enhance Stereotactic Body Radiation Therapy for Frequent Cancers in the Asia-Pacific Region. After establishing Singapore as one of the regional training hubs in Asia- Pacific, Dr. Tan conducted the first regional training course of the project in NCCS in 2016, which was attended by participants from 17 member states. He is also council member of the Federation of Asian Organizations for Radiation Oncology (FARO), which is a non-profit scientific organization comprising national radiation oncology societies in Asia to improve the level of radiotherapy in the region.
On the local front, Dr. Tan serves as Chair of the Radiation Oncology Sub-section of the Singapore Radiological Society (SRS) and is also a fellow in the Academy of Medicine. He has been part of the organizing committee for RadiologyAsia 2015 and 2017, which are regional radiology meetings held bi-annually in conjunction with the SRS Annual Scientific Meetings. As chair of the SRS radiation oncology subsection, Dr. Tan organizes annual scientific dinnersymposiums for the local oncology community to update them on the latest advances in radiotherapy in common tumour sites such as liver, pancreas and prostate malignancies, and on latest technologies such as proton therapy. Dr. Tan also held position as Adjunct Assistant Professor at the Duke-NUS Graduate Medical School where he hosted and supervised medical students for clinical attachments at NCCS, and was clinical lecturer at the Nanyang Polytechnic School of Radiation Therapy where he gave lectures to budding radiation therapists.
What Is the Prognostic Value of the (Y)pN Status After Chemoradiotherapy in Rectal Cancer?
The Promise of Stereotactic Body Radiotherapy – Next phase of integration into oncological practice.
Assessing dose contribution to pelvic lymph nodes in intracavitary brachytherapy for cervical cancer.
Squamous-cell carcinoma of the anus: Progress in radiotherapy treatment Rob Glynne Jones, David Tan, Robert Hughes, Peter Hoskin
Urological reconstruction after pelvic oncological surgery: A single institution experience
Post-operative Chemoradiation for Rectal Cancer
How can we determine the best neoadjuvant chemoradiotherapy regimen for rectal cancer?
How to Select for Preoperative Short-course Radiotherapy, While Considering Long- course Chemoradiotherapy or Immediate Surgery, and Who Benefits?
Pelvic MRI for Guiding Treatment Decisions in Rectal Cancer Rob Glynne-Jones, David Tan B H, Vicky Goh
But some Neoadjuvant Schedules are more Equal than Others David Tan B H, Glynne-Jones Rob
|Fellowships and Accreditations